KAHR Medical Ltd.
Sector: Biotechnology - Therapeutics
Medical Field: Autoimmune Diseases
Technological Field: Immune Modulators
Year Established: 2005
The mission at KAHR Medical is to develop novel fusion protein pharmaceuticals for the treatment of autoimmune diseases. The company’s drug pipeline is built around ‘trans signal converter proteins (TSCP)’ – a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The TSCP technology, licensed from the University of Pennsylvania, offers higher drug efficacy and specificity via multi-functionality and cooperative signal modulation.
KAHR-Medical promises to significantly extend the repertoire of protein pharmaceuticals available for influencing immunity and inflammatory processes, and is currently developing two TSCP drug candidates, KAHR-101 and KAHR-102, towards clinical trials. Both lead products are potential drugs for the treatment of multiple autoimmune diseases. KAHR plans to initially assess these products in clinical trials for the treatment of Psoriasis and Reumatoid Arthritis (RA).